Company / SG&A per Share
Theravance Biopharma, Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.49
FY2025
5-year range
$1.07 / $1.54
FY2021-FY2025
Trend
+3.5%
vs FY2024
Sector context
#100 of 210
Health Care
What the data says
At $1.49, Theravance Biopharma, Inc.'s sg&a per share ranks #111 of 210 in the Health Care sector. SG&A per Share has fluctuated over the past 10 years, ranging from $1.07 in FY2023 to $2.23 in FY2016.
Based on SEC 10-K filings.
1.49 in FY2025 with a 5-year CAGR of -4.8%.
Increased from $1.07 to $1.49 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- -4.8%
- 10-Year CAGR
- -
Sector benchmark
#111 of 210 in Health CareTop 52% of 210This company $1.49 Sector average $40.75
▼
-96.3% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share increased 3.5% year-over-year.
- Ranks #100 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
- Lowest sg&a per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.49 | +3.5% |
| FY2024 | $1.44 | +33.9% |
| FY2023 | $1.07 | -26.3% |
| FY2022 | $1.46 | -5.5% |
| FY2021 | $1.54 | -18.9% |
| FY2020 | $1.90 | +10.9% |
| FY2019 | $1.72 | +10.5% |
| FY2018 | $1.55 | -14.1% |
| FY2017 | $1.81 | -18.7% |
| FY2016 | $2.23 | +99.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026